The receptor for advanced glycation end products (RAGE) 
Introduction
The receptor for advanced glycation end products (RAGE), a multi-ligand member of the immunoglobulin superfamily of cell surface molecules, has been implicated in amplification of proinflammatory responses. 1 S100/calgranulins, proinflammatory signal transduction ligands of the receptor, are enriched in joints of subjects with rheumatoid arthritis (RA). [2] [3] [4] Members of this family of molecules, long-associated with classic immune/ blood-derived monocytes bearing RAGE 82S. Finally, we performed a preliminary study of the distribution of the G82S polymorphism in subjects with RA.
Results

RAGE and murine collagen-induced arthritis
As a first test of the hypothesis that RAGE contributed to inflammatory and tissue-destructive mechanisms in arthritis, we induced arthritis in DBA/1 mice by sensitization and challenge with bovine type II collagen, the predominant protein of articular cartilage. [15] [16] [17] Bovine type II collagen was emulsified in complete Freund's adjuvant and injected intradermally at the base of the tail (day 0). Three weeks later, mice were challenged with bovine type II collagen (day 22). The contribution of RAGE to the pathogenesis of arthritis was studied by treating animals with soluble (s) RAGE, 1, 18 the extracellular ligandbinding domain of the receptor, 100 g per day, beginning 3 weeks after initial immunization (day 22). In previous studies, blockade of RAGE at this dose effected the greatest decrease in the proinflammatory phenotype in a murine model of delayed-type hypersensitivity. 1 The relevance of RAGE-ligand interaction to murine collagen-induced arthritis was underscored by the increased expression of RAGE and S100/calgranulins in joint tissue. Six weeks after immunization, RAGE and S100/calgranulin expression was increased in joints from mice with arthritis compared with controls, especially within the proliferating synovium (RAGE, Figure 1e,d; S100/calgranulin, Figure 1h ,g, respectively). By immunoblotting, levels of RAGE antigen were enhanced 2.2-fold in arthritis vs control joints (Figure 1m ). Although levels of S100/calgranulins were quite low in joint tissue of control DBA/1 mice without collagen-induced arthritis, expression of these proinflammatory mediators was induced in murine serum albumin-treated mice immunized/challenged with bovine type II collagen ( Figure 1n ). In mice subjected to blockade of RAGE with sRAGE, levels of RAGE and S100/calgranulin antigens by immunoblotting were significantly reduced compared to mice treated with vehicle ( Figure 1m ,n respectively).
In parallel with reduced expression of RAGE and S100/calgranulins in sRAGE-treated joints, clinical indices of inflammation 18 were consistently lower in mice treated with sRAGE vs phosphate-buffered saline (PBS) or murine serum albumin (Figure 2a ). In addition, histologic scoring 19 revealed marked decreases in synovial hyperplasia/hypertrophy in the joints of sRAGE-treated mice (Figure 2b ). Further, histologic indices of cartilage and bone destruction 20 were significantly decreased in sRAGE-treated mice compared with those animals receiving PBS or murine serum albumin (Figure 2b ). To determine if blockade of RAGE suppressed immune/inflammatory responses to bovine type II collagen at extra-articular sites, mice receiving vehicle or sRAGE were injected with bovine type II collagen (10 g) into ear tissue 6 weeks after immunization (day 42). Although baseline ear thickness was identical in all groups, 18 hrs after injection of collagen, mice receiving murine serum albumin or PBS revealed significant increases in ear thickness compared with those mice treated with sRAGE ( Figure 2c ). Levels of serum total IgG developed against bovine type II collagen were unchanged in the presence of sRAGE vs PBS or murine serum albumin, thereby indicating that blockade of RAGE did not suppress primary immunization (Figure 2d) .
To dissect the molecular mechanisms underlying the protection afforded by RAGE blockade, we assessed levels of cytokines and matrix metalloproteinases (MMPs) in the tissues. ELISA on extracts prepared from stifle joints revealed a significant reduction in levels of TNF-alpha (4.3-fold) and IL-6 (3.1-fold) from mice immunized with bovine type II collagen treated with sRAGE vs murine serum albumin (Figure 3a,b, respectively) . Similarly, levels of plasma TNF-alpha and IL-6 antigens were significantly reduced, 3.5-and 3.6-fold, in sRAGEtreated mice compared with those animals receiving murine serum albumin (Figure 3c,d, respectively) .
As induction of TNF-alpha and other inflammatory cytokines sets in motion events leading to activation of latent/proenzyme MMPs, 21 we assessed activity of MMPs 3, 9 and 13 in joint tissue. Compared with control joints, tissue retrieved from murine serum albumintreated mice undergoing the collagen-induced arthritis protocol revealed an 2.5-fold, 4.0-fold and 5.3-fold increase in activity of MMPs 3, 9 and 13, respectively, by zymography (Figure 3e ,f). That activation of RAGE was critical in this process was demonstrated by the significant reduction in activation of these MMPs in joint tissue of sRAGE-treated mice (Figure 3e ,f, respectively).
Taken together, these observations suggested that interaction of S100/calgranulins and RAGE, both enriched in joint tissues in arthritis, activates proinflammatory and tissue-destructive mediators, thereby supporting roles for these molecules in the evolution of joint destruction.
RAGE 82S allele enhances binding/signalling/gene expression by S100/calgranulins
Polymorphisms within the RAGE gene may influence these effects by altering proinflammatory pathways. To study this, we tested whether the glycine to serine polymorphism (G82S) within the ligand-binding domain of RAGE displayed enhanced ligand affinity and activation of signal transduction pathways. We prepared stablytransfected CHO cells bearing the two RAGE alleles of interest, either the common RAGE 82G allele, or the variant RAGE 82S allele. CHO cells provide a convenient model, as they are devoid of detectable RAGE prior to (not shown), or after stable transfection with pcDNA3.1 vector alone (mock) (Figure 4a ). Stably-transfected CHO cells were made with pcDNA3.1 containing either RAGE 82G or RAGE 82S (Figure 4a ). ELISA studies demonstrated that levels of RAGE antigen were identical in both CHO cells transfected to express RAGE 82G or RAGE 82S (data not shown). Radioligand binding studies showed dose-dependent binding of 125 I-EN-RAGE (a prototypic S100/calgranulin) to CHO cells expressing RAGE 82G (122 ± 31 nM) and 82S receptor (Kd 77 ± 21 nM), though the affinity of binding was greater with the 82S allele (P = 0.008; Figure 4b ). In contrast, CHO cells stably transfected with the empty vector displayed no specific binding of Six weeks after immunization with bovine type II collagen, murine serum albumin (MSA)-, PBS-and sRAGE-treated mice were injected with bovine type II collagen into ear tissue. Ear thickness was measured by a blinded observer immediately prior to local injection, and 18 hrs later. The mean ± s.d. is shown; n = 5 mice per group. *indicates P Ͻ 0.05 vs ear thickness in PBS-and MSA-treated groups. (d) Antibody response to bovine type II collagen. At the indicated time points after immunization, plasma was retrieved from DBA/1 mice and subjected to ELISA for determination of total serum IgG levels to type II collagen. There were no statistically-significant differences in total IgG levels among the groups.
anti-RAGE IgG, but not by bovine serum albumin (BSA) or nonimmune IgG (Figure 4c ).
These observations led us to test the concept that the 82S RAGE isoform might amplify cellular activation beyond that seen in cells bearing wild-type RAGE. Incubation of mock-transfected CHO cells with a physiologically-relevant concentration of EN-RAGE, 4 10 g/ml, did not significantly increase intensity of the bands corresponding to phosphorylated MEK 1/2 or p44/42 MAP kinases [22] [23] (Figure 4d ,e, respectively; lanes 1-5). However, exposure of RAGE 82G CHO transfectants to EN-RAGE increased by 2.2-fold and 1.9-fold phosphorylated MEK 1/2 and p44/42 MAP kinases, compared with cultures incubated with BSA alone (P Ͻ 0.01; Figure 4d ,e respectively; lanes 7 and 6). CHO transfectants bearing RAGE 82S incubated with EN-RAGE displayed 3.6-fold and 4.1-fold increase in phosphorylated MEK 1/2 and p44/42 compared with BSA (P Ͻ 0.01; Figure 4d ,e respectively; lanes 12 and 11). Thus, compared with cells expressing the common RAGE 82G allele, CHO cells expressing the variant RAGE 82S displayed significantly increased phosphorylation of MEK 1/2 and p44/p42 MAP kinases by 1.6-and 2.2-fold (P Ͻ 0.05; Figure 4d ,e respectively; lanes 12 and 7). In both RAGE 82G and RAGE 82S-transfected cells, cellular activation by EN-RAGE was due to engagement of RAGE as demonstrated by suppression of phosphorylation of MEK 1/2 and p44/p42 by excess sRAGE ( Figure 4d ,e respectively; lanes 8 and 13), or anti-RAGE IgG (Figure 4d ,e respectively, lanes 9 and 14). Nonimmune IgG was without effect ( Figure 4d ,e respectively; lanes 10 and 15). In each case, respective levels of total MEK 1/2 and p44/p42 MAP kinases were identical (data not shown).
To further support the hypothesis that RAGE 82S enhanced activation of key proinflammatory signal transduction pathways, we assessed nuclear translocation of NF-B in CHO transfectants exposed to EN-RAGE. Electrophoretic mobility shift assays (EMSA) using 32 Plabelled consensus NF-B probe and nuclear extracts from mock-transfected CHO cells showed no increase in intensity of the gel shift band after cultures were exposed to EN-RAGE ( Figure 4f , lane 2). In CHO transfectants expressing RAGE 82G, there was a prominent 2.4-fold
Genes and Immunity increase in intensity in nuclear binding activity following incubation of cultures with EN-RAGE compared to BSA (P Ͻ 0.05; Figure 4f , lanes 7 and 6, respectively). NF-B activation was even more striking when RAGE 82S was substituted for RAGE 82G. RAGE 82S CHO transfectants displayed 5.1-fold increased intensity of the gel shift band consequent to the presence of EN-RAGE, compared The indicated stably-transfected CHO cells were incubated with EN-RAGE for 1 h. Immunoblotting of cell lysates was performed using anti-phosphorylated MEK 1/2 (d) or p44/p42 MAP kinase (e). Where indicated, pretreatment with either BSA or sRAGE, or the indicated IgG for 2 h was performed. Control immunoblotting using antibody to total MEK 1/2 and p44/p42 MAP kinase revealed that there were no differences in levels of total MEK 1/2 or p44/p42 (not shown). (f) Activation of NF-B. Nuclear extracts were prepared from the indicated stably-transfected CHO cells incubated with EN-RAGE for 6 h and EMSA was performed. Where indicated, cells were pretreated with either nonimmune/anti-RAGE IgG, soluble RAGE or BSA for 2 h prior to incubation with EN-RAGE. In d,e,f, bands were scanned into a densitometer, and band density was quantified using ImageQuant. These experiments were performed at least three times and subjected to statistical analyses as indicated in the text and the figure legend. Representative experiments are shown.
to incubation with BSA (P Ͻ 0.001; Figure 4f , lanes 12 and 11, respectively). Thus, RAGE-mediated NF-B activation due to EN-RAGE was significantly enhanced by 2.1-fold comparing RAGE 82S to 82G; P Ͻ 0.01. That activation of NF-B in transfected CHO cells by EN-RAGE resulted from ligation of common or variant RAGE was confirmed by its suppression in the presence of sRAGE (Figure 4f , lanes 8 and 13, respectively), or anti-RAGE IgG (Figure 4f , lanes 9 and 14, respectively), but not by nonimmune IgG (Figure 4f, lanes 10 and 15, respectively) .
A critical test of the concept that S100/calgranulin-RAGE 82S interaction might enhance proinflammatory effects was whether mononuclear phagocytes (MPs) retrieved from human subjects bearing the variant RAGE 82S allele displayed heightened activation of signal transduction molecules in the presence of ligand. Due to the rare number of subjects homozygous for 82S in our study populations, we limited our studies to those individuals homozygous for the common RAGE allele 82G, or those subjects heterozygous for 82G and 82S alleles. ELISA revealed that basal levels of RAGE antigen did not differ between MPs bearing 82G or 82G/82S (data not shown). Signalling was compared in MPs from subjects bearing RAGE 82G and RAGE 82G/82S by assessing activation of MEK 1/2 and p44/p42 MAP kinases. In the presence of EN-RAGE, MPs isolated from individuals bearing RAGE 82G/82S displayed an 4.5-and 4.3-fold increase in phosphorylated MEK 1/2 and p44 and p42 MAP kinases, respectively, compared with unstimulated cells (P Ͻ 0.01; Figure 5a -d). However, MPs bearing the common RAGE 82G allele exposed to EN-RAGE revealed a significant, although smaller (2.6-and 2.3-fold) increase in activation of MEK 1/2 and p44/p42 MAP kinases, respectively (P Ͻ 0.01; Figure 5a-d) . Importantly, EN-RAGE-triggered activation of MEK 1/2 and p44/p42 MAP kinases was significantly increased in heterozygous RAGE 82G/82S-bearing MPs vs those MPs expressing RAGE 82G (P Ͻ 0.05; Figure 5b,d) .
To assess the functional consequences of enhanced binding and activation of signal transduction molecules stimulated upon ligation of RAGE by EN-RAGE, we examined production of key inflammatory and tissuedegradative mediators linked to RA [24] [25] [26] by MPs bearing common or variant RAGE alleles. Exposure of RAGE 82G-bearing MPs to EN-RAGE caused a significant increase in generation of TNF-alpha detected in culture supernatant compared with quiescent cultures (470 ± 53 vs 15 ± 2 pg/ml; P Ͻ 0.001) (Figure 5e ). However, upon incubation of human MPs bearing RAGE 82G/82S, an even greater increase in elaborated TNF-alpha was observed in culture supernatants compared with basal levels (850 ± 64 vs 17 ± 2 pg/ml; P Ͻ 0.01) (Figure 5e ). Importantly, although basal levels of TNF-alpha did not differ between RAGE 82G and 82G/82S-bearing MPs, levels of TNF-alpha in EN-RAGE-stimulated MPs were increased 1.8-fold in the presence of RAGE 82G/82S compared with RAGE 82G (P Ͻ 0.01; Figure 5e ). Similarly, RAGE 82G-bearing MPs exposed to EN-RAGE displayed a small, but significant increase in generation of IL-6 compared with basal expression (55 ± 7 vs 15 ± 2 pg/ml; P Ͻ 0.01) (Figure 5f ). However, MPs bearing RAGE 82G/82S revealed augmented generation of IL-6 upon incubation with EN-RAGE compared with unstimulated controls (160 ± 14 vs 12 ± 2 pg/ml; P Ͻ 0.01) (Figure 5f ). EN-RAGE-stimulated MPs bearing RAGE 82G/82S generated increased amounts of IL-6 compared with cells from subjects bearing RAGE 82G (2.9-fold) (P Ͻ 0.01; Figure 5f ).
A central means by which structural elements of joints are degraded in unchecked RA is by generation of MMPs, such as MMP-9. [27] [28] [29] [30] We hypothesized that RAGEmediated MP activation would augment generation of MMP activity on cells bearing RAGE 82G/82S vs RAGE 82G. We tested activity of MMP-9 in MPs retrieved from subjects bearing the common or variant RAGE alleles. MPs from subjects bearing RAGE 82G displayed a 2.3-fold increase in MMP-9 activity in the presence of EN-RAGE compared with basal expression (P Ͻ 0.01; Figure 5g ,h). However, MPs isolated from individuals bearing RAGE 82G/82S demonstrated a 4.3-fold increase in EN-RAGE-mediated MMP-9 activity compared with baseline (P Ͻ 0.01; Figure 5g ,h). Although basal levels of MMP-9 activity did not differ among 82G-or 82G/82S-bearing MPs, the extent of EN-RAGE-mediated enhanced MMP-9 activity was significantly enhanced, 1.9-fold, in MPs bearing RAGE 82G/82S vs RAGE 82G (P Ͻ 0.05; Figure 5g ,h).
Taken together, our studies in DBA/1 mice suggest that activation of RAGE amplifies cytokine generation and activation of MMPs in joint tissue primed by immunization with bovine type II collagen. These considerations, together with our findings in vitro suggesting that S100/calgranulin-RAGE interaction modifies cellular responses, especially in the presence of the 82S allele, led us to evaluate the association of the RAGE 82S allele with RA.
Genes and Immunity
RAGE 82S allele and association with rheumatoid arthritis
Subjects from a previously-reported Caucasian population of RA patients (n = 205) and matched controls (n = 169) 31 were evaluated. The RAGE 82S allele exhibited an association with RA with relative risk (RR) = 2.6, P Ͻ 0.001 (Table 1a) . Further analyses were performed to account for the linkage disequilibrium described previously between RAGE 82S and an RA-associated allele, HLA-DRB*0401. 9, [32] [33] [34] To assess whether the RAGE 82S allele confers risk independent of DRB1*0401, we compared the frequency of the RAGE 82S allele in 0401+ patients and controls.
This analysis did not reveal a significant independent effect of RAGE 82S on RA disease susceptibility; P = 0.13 by Fisher's exact test (Table 1b) . However, DRB1*0401 continued to exhibit a significant association with RA in the absence of the RAGE 82S allele (Table 1c) . Discussion S100/calgranulin molecules have been extensively linked to immune/inflammatory diseases. Although their intracellular functions are relatively well-defined, such as calcium-dependent chemotaxis, degranulation and phagocytosis by activated granulocytes, 5, 6, 35 an increasingly recognized view is that these molecules may exhibit distinct functions in the extracellular milieu. 35 These concepts are consistent with the observations that the degree of elevation of S100/calgranulins in inflamed foci may mirror the extent of disease activity. For example, in addition to their association with disease severity in RA, 4 S100/calgranulins have been linked to disease progression in inflammatory bowel disease. 36, 37 Furthermore, strongly increased expression of a member of this family of molecules, psoriasin, has been demonstrated in psoriatic lesions compared with adjacent unaffected skin in human subjects, 38 thus further supporting the premise that S100/calgranulins may not simply be 'innocent bystanders', but, rather, by virtue of their engagement of RAGE, 1 active participants in the host inflammatory response. We speculate that triggered by interaction with accumulating S100/calgranulins, activation of RAGE engages key signalling pathways linked to proinflammatory responses, such as MAP kinases and NF-B, thereby amplifying expression of molecules linked to chronic cellular perturbation and tissue destruction. This hypothesis appears to be supported by our studies in DBA/1 mice immunized/challenged with bovine type II collagen, as activation of RAGE mediated, at least in part, increased generation of inflammatory cytokines and activation of MMPs. Indeed, blockade of the receptor was associated with decreased clinical and histologic indices of inflammation and bone/cartilage destruction in this model.
Polymorphic differences in the RAGE gene may lead to varied effects of RAGE in inflammatory settings. This led us to investigate the effects of the G82S polymorphism in the binding domain of RAGE on receptor function and on the inflammatory response. In transfected CHO cells, increased ligand affinity was found to be conferred by the 82S isoform, which, upon further analysis, demonstrated upregulation of intracellular signalling pathways linked to modulation of proinflammatory genes upon interaction with S100/calgranulin. Using Figure 5 Human peripheral blood mononuclear phagocytes (MPs) expressing RAGE 82S display increased responsiveness to EN-RAGE. MPs were purified from the blood of human subjects bearing RAGE (G82G) (n = 5) or heterozygotes (G82S) (n = 5). (a-d) Activation of MEK 1/2 and p44/p42 MAP kinases: The indicated MPs were incubated with EN-RAGE or no mediator for 1 h. Cell lysates were prepared and immunoblotting performed using anti-phosphorylated MEK 1/2 (a,b) or p44/p42 MAP kinase (c,d). Densitometric analysis was performed and mean ± s.d. is shown in b and d. Immunoblotting using antibody to total MEK 1/2 and p44/p42 MAP kinase revealed that there were no differences in levels of total MEK 1/2 or p44/p42 (not shown). (e,f) Generation of TNF-alpha and IL-6: Human MPs bearing the indicated RAGE alleles were cultured in the presence of either no mediator or EN-RAGE for 14 h. Supernatants were retrieved and levels of TNF-alpha (e) and IL-6 (f) determined by ELISA. The mean ± s.d. is shown. (g,h) MMP-9 activity: Human MPs bearing the indicated RAGE alleles were cultured in the presence of either no mediator or EN-RAGE for 14 h. Supernatants were retrieved and subjected to zymography to assess levels of activated MMP-9. In b, d, and h, bands from n = 5 G82G and n = 5 G82S subjects were scanned into a densitometer and band density was quantified. Representative experiments are shown. The mean ± s.d. is shown. In b, d, e, f and h, *indicates P Ͻ 0.01 vs baseline. isolated MPs from human subjects, we demonstrated significant differences in inflammatory responses between cells isolated from homozygous wild-type G82G and heterozygous G82S subjects. These effects were quite marked between wild-type and heterozygote subjects, thereby suggesting that the 82S allele alone may impart an even greater effect, a premise which requires further study. Finally, we investigated the prevalence of the 82S allele in a population of subjects with RA. Our results demonstrated a statistically-significant increase in prevalence of the 82S allele in subjects with RA. Sub-analysis for the presence/absence of DRB1*0401 led to the loss of an statistically-significant association of 82S with RA (P = 0.13 despite odds ratio 3.2). Conversely, DRB1*0401 continued to exhibit a significant association with RA in the absence of the RAGE 82S allele. Clearly, the large genetic susceptibility to RA related to the MHC 39, 40 cannot be ascribed solely to the RAGE 82S allele. Due to the relatively low frequency of the 82S allele and low subject numbers in these Caucasian cases and controls after sub-analysis, it remains possible that the RAGE G82S polymorphism is related independently to RA. This issue requires further study.
The literature is conflicting with respect to a role for DR4 haplotypes in disease severity. [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] In view of the linkage disequilibrium between DRB1*0401 and the RAGE 82S allele, it will be interesting to specifically test whether DR4 haplotypes containing the RAGE 82S allele have an influence on disease progression and outcome. By analogy with our observations in cultured CHO and human mononuclear cells, we speculate it may be possible to identify a subset of subjects with RA particularly vulnerable to the sequelae of heightened production/activation of proinflammatory mediators. Specifically, in parallel with outcome measures of clinical severity, such as numbers of bony erosions, the extent of elevation of TNF-alpha, IL-6 and MMP activities in rheumatoid joint fluid and/or RA plasma must be correlated with subject genotype.
A general implication of these studies is that the classical DRB1 associations with RA may not completely explain the underlying reasons for the strong linkage and association of the MHC with RA. Indeed, a number of Genes and Immunity recent reports indicate that additional genes in the TNF region may influence disease susceptibility, independent of DRB1, and unrelated to DR4 haplotypes. [51] [52] In our view, a full understanding of the role of the MHC in RA and other autoimmune diseases will require a more detailed analysis of this genetic region, since there are many genes within the MHC, in addition to RAGE, which may influence the immune/inflammatory response. 53 Lastly, in addition to the 82S variant of the RAGE gene, it will be important to examine the potential role of other variants of RAGE in disease susceptibility and/or severity in immune/inflammatory diseases. In this context, recently identified polymorphisms within the promoter of the gene encoding RAGE may hold the key to unique elements controlling enhanced transcription of the RAGE gene and increased expression of cell surface RAGE. 54 As a number of studies have suggested that expression of RAGE is increased at sites of ligand accumulation such as diabetic atherosclerotic lesions, infected periodontium or Alzheimer disease brain, 13, 18, 55 polymorphisms within regulation elements and/or ligand-binding regions may, alone or in combination, orchestrate RAGE's availability and/or functional potential in a given milieu. 56 In conclusion, we propose that these observations in an animal model of inflammatory arthritis and in S100/calgranulin-stimulated activation of 82S RAGEbearing cells highlight ligand-RAGE engagement as an amplifier of proinflammatory mechanisms in immune/ inflammatory diseases. These findings provide a compelling rationale to expand the analysis of RAGE polymorphisms and investigate their potential contribution to susceptibility and/or progression of the inflammatory response in diverse diseases with an immune/ inflammatory component, such as RA, atherosclerosis and diabetes.
Materials and methods
Murine model of bovine collagen type II-induced arthritis
Induction of arthritis: Male DBA/1 mice were purchased from the Jackson Laboratories (Bar Harbor, ME, USA). On day 0, mice weighing 20-30 gms were injected intradermally at the base of the tail with bovine type II collagen, 200 g (Sigma, St Louis, MO, USA), dissolved in acetic acid (0.01 M) and emulsified in complete Freund's adjuvant (ICN Biochemcials, Costa Mesa, CA, USA). Three weeks later (day 22), mice were challenged by injection of bovine collagen type II (200 g) in incomplete Freund's adjuvant. [15] [16] [17] Beginning 3 weeks after immunization (day 22), mice were treated with murine soluble RAGE 1 (100 g per day by intraperitoneal route). Vehicle treatment consisted of murine serum albumin (Sigma), 100 g per day by intraperitoneal injection, or equal volumes of PBS. Treatment was continued daily until sacrifice. All murine studies were performed in accordance with the policies of the university's Institutional Animal Care and Use Committee.
Determination of anti-collagen IgG:
ELISA was performed to determine levels of IgG to bovine type II collagen in dba/1 mice. Plastic Maxisorp 96-well plates (Nunc, Naperville, IL, USA) were coated with bovine type II collagen (5 g/ml) in bicarbonate/carbonate buffer; pH 9.3 for 16 h at 4°C. Unbound sites were blocked with PBS containing BSA (1%) for 8 h at 4°C. Wells were washed five times in PBS and then incubated for 16 h in samples of mouse plasma (dilution, 1:50) in PBS at 4°C. Wells were washed five times with PBS and incubated with PBS containing 1% BSA and horse radish peroxidase-labelled anti-mouse IgG (Sigma; 1:500 dilution) for 2 h at room temperature. Wells were washed with PBS five times and developed using o-phenylenediamine dihydrochloride (Sigma). A standard curve was prepared using serial dilutions from a mouse antibody cocktail against bovine type II collagen (Chemicon, Temecula, CA, USA).
Assessment of arthritis:
Arthritis was evaluated by clinical and histologic scoring by observers blinded to the experimental conditions. Clinical severity of arthritis in each of four limbs was assessed by the following scale: 19 0 = normal; 1 = slight erythema and swelling; 2 = pronounced edematous swelling; and 3 = joint deformity with ankylosis, resulting in a maximum score of 12 per animal. Histologic scoring of arthritis and cartilage and bone destruction was performed on hematoxylin and eosin-stained sections of extremity joints by the following scale: 20 (i) synovial lesions: 0, no lesions; 1: mild effect; 2: moderate effect/proliferation; 3: severe lesions with destruction; (ii) cartilage destruction: 0, none; 1, mild; 2, moderate; 3, severe destruction with loss or complete fragmentation of cartilage; and (iii) bone destruction: 0, none; 1, mild destruction of subchondral bone; 2, moderate destruction; and 3, severe destruction with loss of large areas of bone. In other studies, 6 weeks after initial sensitization, bovine type II collagen (10 g) was injected into the ear of each mouse. Eighteen hours later, thickness of the ear was assessed using calipers by an observer blinded to the experimental conditions.
Immunoblotting and ELISA: Mice were sacrificed 3 or 6 weeks after challenge. The stifle joint was removed and homogenized in tris-buffered saline containing protease inhibitors (Complete Protease Inhibitor, BoehringerMannheim, Indianapolis, IN, USA). SDS-PAGE and immunoblotting were performed on extracts of stifle joint tissue using the following antibodies: anti-RAGE IgG and anti-S100/calgranulin IgG as previously described 1 (4.7 and 2.0 g/ml, respectively). ELISA for TNF-alpha and IL-6 was performed using kits from R&D Systems (Minneapolis, MN, USA).
Zymography: Zymography for detection of MMP-3, 9 and 13 activity was performed using gelatin or casein-laden gels from Novex/Invitrogen (Carlsbad, CA, USA).
Chinese hamster ovary (CHO) cell studies CHO cells were obtained from ATCC (Rockville, MD, USA) and cultured in F12 medium containing fetal bovine serum (10%) (Life Technologies, Grand Island, NY, USA). To generate the 82S allele, the cDNA encoding human RAGE 10 was cloned using the TOPO TA cloning system into pCR2.1TOPO vector for mutagenesis (Invitrogen). Site-directed mutagenesis to insert the (Ϫ82GϪ) to (Ϫ82SϪ) change was performed using the GeneEditor In Vitro SDM System (Promega, Madison, WI, USA). Sequencing was performed using an ABI310 automated DNA sequencer (Perkin Elmer Biosystems, Foster City, CA, USA) to confirm the inserted sequence changes and to ensure that no other mutations were created. RAGE 82G and 82S cDNAs were excised from pCR2.1TOPO using EcoR I and subcloned into the pcDNA3.1 expression vector (Invitrogen). Cells were transfected with plasmid DNA using lipofectamine (Life Technologies) encoding the following: pcDNA3.1 containing full-length RAGE cDNA (−82G−), pcDNA3.1 containing RAGE cDNA (−82S−), or pcDNA3.1 containing no insert (mock). Twenty-four hours after transfection, selection was begun using G418 (1 mg/ml) (Life Technologies). RAGE expression was assessed by immunoblotting in stably-transfected cells after 6 weeks. Cells were incubated with EN-RAGE (Extracellular NewlyIdentified RAGE binding protein), a prototypic S100/calgranulin molecule previously-identified to be a signal transduction ligand for RAGE, 1 or the indicated mediators. Assessment of activation of phosphorylated MEK 1/2 and p44/p42 MAP kinase by immunoblotting or nuclear translocation of NF-kB was performed. All reagents were tested for endotoxin content using the limulus amebocyte assay (Sigma). Any endotoxin identified in these assays was removed by chromatography of the protein solutions onto Detox-igel columns (Pierce, Arlington Hts, IL, USA). The material was re-tested in the limulus amebocyte assay for the absence of detectable endotoxin.
Radioligand binding assays: Purified EN-RAGE was radiolabelled using 125 -I and Iodobeads (Pierce, Arlington Heights, IL, USA) to a specific activity of approximately 5000 cpm/ng. Radioligand binding assays were performed in 96-well tissue culture dishes containing the indicated transfected CHO cells in the presence of the indicated concentration of radiolabelled EN-RAGE ± a 50-fold molar excess of unlabelled EN-RAGE in PBS containing calcium/magnesium and BSA, 0.2%, for 3 h at 37°C. Wells were washed rapidly with washing buffer (PBS containing Tween 20 (0.05%)). Elution of bound material was performed in a solution containing heparin, 1 mg/ml. The aspirate was counted in a gamma counter (LKB, Gaithersburg, MD, USA). Equilibrium binding data were analyzed according to the equation of Klotz and Hunston: 57 B = nKA/1 + KA, where B = specifically bound ligand (total binding, wells incubated with tracer alone, minus nonspecific binding, wells incubated with tracer in the presence of excess unlabelled material), n = sites/cell, K = the dissociation constant, and A = free ligand concentration) using nonlinear least-squares analysis (Prism, San Diego, CA, USA). Where indicated, pretreatment with antibodies (70 g/ml), or human soluble RAGE (50-fold molar excess), was performed.
Activation of pMEK 1/2 and p44/p42 MAP kinases: CHO cells were incubated with EN-RAGE, 10 g/ml, for 1 h. Cells were lysed in lysis buffer (New England Biolabs, Beverly, MA, USA) and lysate was subjected to centrifugation. Protein concentration of the supernatant was determined by Bio-Rad assay (Bio-Rad, Hercules, CA, USA). Equal amounts of protein were subjected to SDS-PAGE (Novex/Invitrogen). Contents of the gels were transferred to nitrocellulose and immunoblotting performed using anti-phosphorylated/total p44/p42 MAP kinase and MEK 1/2 (New England Biolabs) (1 g/ml).
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Electrophoretic mobility shift assay: Nuclear extracts were prepared using the NE kit (Pierce) and EMSA performed employing consensus 32 P-labelled probe for NF-kB as described. 1 Where indicated, cells were treated with either nonimmune/anti-RAGE IgG, or soluble RAGE.
1,21
Peripheral blood-derived mononuclear phagocyte (MPs) studies Cellular isolation: Venous blood was obtained from healthy volunteers (30 ml) bearing RAGE 82G or 82G/82S in accordance with the policies of the university's Institutional Review Board. Due to the rare numbers of subjects homozygous for the 82S allele, our studies were confined to those bearing solely 82G or heterozygous 82G/82S. Mononuclear cells were isolated using Histopaque 1077 (Sigma) and cultured on plastic dishes for 3 h at 37°C. Nonadherent cells were removed by washing in PBS. Adherent cells were removed by incubation with EDTA (2 mM) for 15 mins at 37°C. Cells (Ͼ95% MPs as assessed by immunostaining with anti-CD68 IgG) were seeded in tissue culture-coated wells for study.
Activation of phosphorylated MEK 1/2 and p44/p42 MAP kinases and generation of IL-6 and TNF-alpha:
MPs were seeded onto the wells of 24-well tissue culture plates at a density of 5 × 10 5 cells per well. Cells were stimulated with either BSA or EN-RAGE (10 g/ml), and immunoblotting for detection of phosphorylated/total MEK 1/2 and p44/p42 MAP kinases performed as above. Supernatant was assayed for IL-6 and TNF-alpha using ELISA kits from R&D systems (Minneapolis, MN, USA).
Patient population and detection of 82S polymorphism RA patients used for association studies meet the criteria of the American College of Rheumatology 58 and were taken from patient populations collected previously at the Medical College of Virginia, Virginia Commonwealth University. 31 The following primers were synthesized for detection of the glycine82serine (G82S) polymorphism of the RAGE gene: 8 sense primer: 5′ GTAAGCG GGGCTCCTGTTGCA-3′ and the antisense primer: 5′ GGCCAAGGCTGGGGTTGAAGG-3′. Whole blood (20 l) was obtained from human volunteers in accordance with the standards and policies of the Institutional Review Boards of the institutions. Genomic DNA was prepared using a kit from Qiagen (Valencia, CA, USA); 10 ng was amplified using Taq DNA polymerase (Life Technologies) in a final volume of 25 l and PCR performed as follows: 94°C for 30 secs, 62°C for 45 s, and 72°C for 60 s for a total of 35 cycles. PCR product (25 l) was digested with Alu I (Life Technologies), 3 U for 16 h at 37°C, followed by electrophoresis on 2% agarose gels.
Statistical analysis
Statistical comparisons were determined using one-way analysis of variance (ANOVA); where indicated, individual comparisons were performed using Student's t-test. For cell culture studies, immunoblotting, zymography and electrophoretic mobility shift assays were performed at least three times. Statistical analyses were performed across each of the experiments by scanning gels/ autoradiograms into a densitometer. Arbitrary units of intensity (Image Quant/Molecular Dynamics (Foster City, CA, Genes and Immunity USA)) were then standardized using untreated cells as control, and assigned a value of '1'. Similarly, in animal studies, an arbitrary value of '1' was assigned to bands (immunoblotting or zymography) in assays from animals without collagen-induced arthritis). Statistical analyses to identify the incidence of G82S in human subjects were performed as previously described.
59-60 P Ͻ 0.05 was considered statistically significant.
